Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Insight Molecular Diagnostics Inc.OCX · Entity 6631 | Director | June 24, 2022 | July 19, 2022 |
| Lineage Cell Therapeutics, Inc.BTX · Entity 6045 | Director | July 01, 2018 | July 03, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Insight Molecular Diagnostics Inc.
Report date June 24, 2022 · Filed July 19, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, no par valueSEC Table I · non-derivative | Direct | 120,863 |
Reported balance
After 2022-06-24 transaction · row 1
1 source rowRow 1 · 2022-06-24 · Exercise / conversion · Acquired 10,000 · Balance 120,863 |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2022-06-24 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-06-24 · Exercise / conversion · Disposed 10,000 · Balance 0 F1: The Restricted Stock Units vested on June 24, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: The Restricted Stock Units vested on June 24, 2022.
Lineage Cell Therapeutics, Inc.
Report date July 01, 2018 · Filed July 03, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option to Purchase Common SharesSEC Table II · derivative / convertible security · Conversion / exercise price $2.06 · Expires 2023-06-30 | Direct | 40,000 |
Reported balance
After 2018-07-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-07-01 · Grant · Acquired 40,000 · Balance 40,000 F1: Will become exercisable on June 30, 2019, based upon continued service on the board of directors. |
| Option to Purchase Common SharesSEC Table II · derivative / convertible security · Conversion / exercise price $2.64 · Expires 2023-02-20 | Direct | 60,000 |
Reported balance
Holding disclosure · report date 2018-07-01 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 60,000 F2: Will become exercisable on February 21, 2019, based upon continued service on the board of directors. |
Filing footnotes · ownership attribution and instrument terms
F1: Will become exercisable on June 30, 2019, based upon continued service on the board of directors.
F2: Will become exercisable on February 21, 2019, based upon continued service on the board of directors.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
PFIZER INC
Report date May 31, 2012 · Filed June 01, 2012
Section 16 reporting ended · disclosed 2012-06-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Phantom Stock Units SSPSEC Table II · derivative / convertible security | Direct | 1,211 |
Reported balance
After 2012-05-31 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2012-05-31 · Grant · Acquired 60 · Balance 1,211 F1: Each unit represents one phantom share of common stock. F2: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. |
Filing footnotes · ownership attribution and instrument terms
F1: Each unit represents one phantom share of common stock.
F2: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 24, 2022 Filed Jul 19, 2022 16:05 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | Exercise / conversionRestricted Stock Units · Derivative | 10,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001493152-22-019823 · ownership.xml · derivative · entry 2 Redmond Cavan M. · CIK 0001420120 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The Restricted Stock Units vested on June 24, 2022. F1 · derivative.expiration_date: The Restricted Stock Units vested on June 24, 2022. Read SEC document |
| June 24, 2022 Filed Jul 19, 2022 16:05 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | Exercise / conversionCommon Stock, no par value | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-22-019823 · ownership.xml · nonDerivative · entry 1 Redmond Cavan M. · CIK 0001420120 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,863 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 16, 2022 Filed Mar 16, 2022 21:08 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | PurchaseCommon Stock, no par value | 40,000 | $1.19 | $47,560.00 |
DisclosureSEC source: 0001493152-22-007054 · ownership.xml · nonDerivative · entry 1 Redmond Cavan M. · CIK 0001420120 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,863 Read SEC document |
| June 24, 2021 Filed Jun 28, 2021 20:36 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | GrantRestricted Stock Units · Derivative | 10,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001493152-21-015451 · ownership.xml · derivative · entry 2 Redmond Cavan M. · CIK 0001420120 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2022-06-24 F2 · derivative.exercise_date: The Restricted Stock Units shall vest one year from the date of grant, subject to the director's continued service as a director of the Company from the date of grant until the vesting date or, if earlier, until the next annual meeting of shareholders. Read SEC document |
| June 24, 2021 Filed Jun 28, 2021 20:36 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | GrantOption to Purchase Common Stock · Derivative | 45,000 | $0.00 Strike: $5.46 | $0.00 |
DisclosureSEC source: 0001493152-21-015451 · ownership.xml · derivative · entry 1 Redmond Cavan M. · CIK 0001420120 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2031-06-23 F1 · derivative.exercise_date: Options shall vest one year from the date of grant, subject to the director's continued service as a director of the Company from the date of grant until the vesting date or, if earlier, until the next annual meeting of shareholders. Read SEC document |
| December 11, 2020 Filed Dec 15, 2020 06:17 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | GrantCommon Stock | 18,416 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-20-023588 · ownership.xml · nonDerivative · entry 1 Redmond Cavan M. · CIK 0001420120 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,863 F1 · price: The shares of the Issuer's common stock were issued to the Reporting Person for the repayment of deferred compensation in lieu of cash at a price of $2.07 per share. Read SEC document |
| June 17, 2020 Filed Jun 19, 2020 17:37 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | GrantOption to purchase common stock · Derivative | 62,000 | $0.00 Strike: $2.38 | $0.00 |
DisclosureSEC source: 0001493152-20-011545 · ownership.xml · derivative · entry 1 Redmond Cavan M. · CIK 0001420120 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,000 Underlying: Common Stock · 62,000 shares Expires not disclosed F1 · derivative.exercise_date: Options shall vest one year from the date of grant, subject to the director's continued service as a director of the Company or a subsidiary from the date of grant until the vesting date or, if earlier, until the next annual meeting of shareholders. F1 · derivative.expiration_date: Options shall vest one year from the date of grant, subject to the director's continued service as a director of the Company or a subsidiary from the date of grant until the vesting date or, if earlier, until the next annual meeting of shareholders. Read SEC document |
| July 17, 2019 Filed Jul 19, 2019 21:38 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | GrantOption to Purchase Common Stock · Derivative | 50,000 | $0.00 Strike: $2.12 | $0.00 |
DisclosureSEC source: 0001209191-19-042849 · doc4.xml · derivative · entry 1 Redmond Cavan M. · CIK 0001420120 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2029-07-16 F1 · derivative.exercise_date: Options shall vest one year from the date of grant, subject to the director's continued service as a director of the Company or a subsidiary from the date of grant until the vesting date or, if earlier, until the next annual meeting of shareholders. Read SEC document |
| August 30, 2018 Filed Sep 4, 2018 21:37 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | GrantOption to Purchase Common Stock · Derivative | 50,000 | $0.00 Strike: $2.40 | $0.00 |
DisclosureSEC source: 0001209191-18-049410 · doc4.xml · derivative · entry 2 Redmond Cavan M. · CIK 0001420120 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2028-08-29 F1 · derivative.exercise_date: Options shall vest one year from the date of grant, subject to the director's continued service as a director of the Company or a subsidiary from the date of grant until the vesting date or, if earlier, until the next annual meeting of shareholders. Read SEC document |
| July 26, 2018 Filed Jul 31, 2018 21:39 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | PurchaseCommon stock purchase warrants · Derivative | 52,447 | Not disclosed Strike: $3.00 | Not disclosed |
DisclosureSEC source: 0001493152-18-010763 · ownership.xml · derivative · entry 2 Redmond Cavan M. · CIK 0001420120 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,447 Underlying: Common stock · 52,447 shares Expires 2024-02-01 F1 · price: The shares of common stock and the common stock purchase warrants reported in this Form were purchased in "units," with each unit consisting of one share of common stock and one common stock purchase warrant. The purchase price per unit was $2.86. Read SEC document |
| July 26, 2018 Filed Jul 31, 2018 21:39 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | PurchaseCommon stock, no par value | 52,447 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-18-010763 · ownership.xml · nonDerivative · entry 1 Redmond Cavan M. · CIK 0001420120 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,447 F1 · price: The shares of common stock and the common stock purchase warrants reported in this Form were purchased in "units," with each unit consisting of one share of common stock and one common stock purchase warrant. The purchase price per unit was $2.86. Read SEC document |
| July 01, 2018 Filed Jul 3, 2018 22:26 UTC | Lineage Cell Therapeutics, Inc. BTX · Entity 6045 | GrantOption to Purchase Common Shares · Derivative | 40,000 | $0.00 Strike: $2.06 | $0.00 |
DisclosureSEC source: 0001209191-18-041306 · doc4.xml · derivative · entry 1 Redmond Cavan M. · CIK 0001420120 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Shares · 40,000 shares Expires 2023-06-30 F1 · derivative.exercise_date: Will become exercisable on June 30, 2019, based upon continued service on the board of directors. Read SEC document |
| June 15, 2017 Filed Jun 19, 2017 21:26 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | GrantOption to Purchase Common Stock · Derivative | 20,000 | $0.00 Strike: $5.10 | $0.00 |
DisclosureSEC source: 0001209191-17-040982 · doc4.xml · derivative · entry 2 Redmond Cavan M. · CIK 0001420120 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2027-06-14 F2 · derivative.exercise_date: Will become exercisable in four equal installments on September 30, 2017, December 31, 2017, March 31, 2018, and one day before the Company's next annual meeting of shareholders, based upon continued service on the board of directors from the date of grant on June 15, 2017. Read SEC document |
| June 15, 2017 Filed Jun 19, 2017 21:26 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | GrantOption to Purchase Common Stock · Derivative | 6,520 | $0.00 Strike: $5.10 | $0.00 |
DisclosureSEC source: 0001209191-17-040982 · doc4.xml · derivative · entry 1 Redmond Cavan M. · CIK 0001420120 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,520 Underlying: Common Stock · 6,520 shares Expires 2027-06-14 F1 · shares: Options are granted to directors annually. These options are a "transitional grant" reflecting the change in the date of the annual grant from February to the date of the annual meeting of shareholders. The options are 32.60% of the annual grant for the 119-day gap between February 16, 2017, one year from the last annual grant, and June 15, 2017, date of the full annual grant for 2017-2018. F2 · derivative.exercise_date: Will become exercisable in four equal installments on September 30, 2017, December 31, 2017, March 31, 2018, and one day before the Company's next annual meeting of shareholders, based upon continued service on the board of directors from the date of grant on June 15, 2017. Read SEC document |
| May 31, 2012 Filed Jun 1, 2012 21:35 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 60 | $21.87 | $1,312.20 |
DisclosureSEC source: 0001225208-12-013547 · doc4.xml · derivative · entry 1 Redmond Cavan M. · CIK 0001420120 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,211 Underlying: Common Stock · 60 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| May 15, 2012 Filed May 16, 2012 19:32 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 69 | $22.30 | $1,538.70 |
DisclosureSEC source: 0001225208-12-012559 · doc4.xml · derivative · entry 1 Redmond Cavan M. · CIK 0001420120 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,151 Underlying: Common Stock · 69 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| April 30, 2012 Filed May 1, 2012 20:59 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 15 | $22.90 | $343.50 |
DisclosureSEC source: 0001225208-12-010669 · doc4.xml · derivative · entry 1 Redmond Cavan M. · CIK 0001420120 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,082 Underlying: Common Stock · 15 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| February 23, 2012 Filed Feb 27, 2012 23:04 UTC | PFIZER INC PFE · Entity 2863 | GrantStock Appreciation Rights · Derivative | 92,593 | $0.00 Strike: $21.03 | $0.00 |
DisclosureSEC source: 0001225208-12-005638 · doc4.xml · derivative · entry 5 Redmond Cavan M. · CIK 0001420120 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,593 Underlying: Common Stock · 92,593 shares Expires 2019-02-23 F3 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F3 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 23, 2012 Filed Feb 27, 2012 23:04 UTC | PFIZER INC PFE · Entity 2863 | GrantStock Appreciation Rights · Derivative | 109,223 | $0.00 Strike: $21.03 | $0.00 |
DisclosureSEC source: 0001225208-12-005638 · doc4.xml · derivative · entry 4 Redmond Cavan M. · CIK 0001420120 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,223 Underlying: Common Stock · 109,223 shares Expires 2017-02-23 F2 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F2 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 23, 2012 Filed Feb 27, 2012 23:04 UTC | PFIZER INC PFE · Entity 2863 | GrantCommon Stock | 21,206 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-12-005638 · doc4.xml · nonDerivative · entry 1 Redmond Cavan M. · CIK 0001420120 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,138 F1 · shares: The reported transaction constitutes the grant of restricted stock units, which are subject to certain vesting requirements. Read SEC document |
| February 24, 2011 Filed Mar 1, 2011 00:07 UTC | PFIZER INC PFE · Entity 2863 | GrantStock Appreciation Rights · Derivative | 91,876 | $0.00 Strike: $18.90 | $0.00 |
DisclosureSEC source: 0001225208-11-007689 · doc4.xml · derivative · entry 4 Redmond Cavan M. · CIK 0001420120 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,876 Underlying: Common Stock · 91,876 shares Expires 2018-02-24 F3 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F3 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 24, 2011 Filed Mar 1, 2011 00:07 UTC | PFIZER INC PFE · Entity 2863 | GrantStock Appreciation Rights · Derivative | 110,981 | $0.00 Strike: $18.90 | $0.00 |
DisclosureSEC source: 0001225208-11-007689 · doc4.xml · derivative · entry 3 Redmond Cavan M. · CIK 0001420120 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,981 Underlying: Common Stock · 110,981 shares Expires 2016-02-24 F2 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F2 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 24, 2011 Filed Mar 1, 2011 00:07 UTC | PFIZER INC PFE · Entity 2863 | GrantCommon Stock | 37,851 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-11-007689 · doc4.xml · nonDerivative · entry 1 Redmond Cavan M. · CIK 0001420120 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,263 F1 · shares: The reported transaction constitutes the grant of restricted stock units, which are subject to certain vesting requirements. Read SEC document |
| February 25, 2010 Filed Mar 2, 2010 02:01 UTC | PFIZER INC PFE · Entity 2863 | GrantStock Appreciation Rights · Derivative | 90,090 | $0.00 Strike: $17.69 | $0.00 |
DisclosureSEC source: 0001225208-10-006401 · doc4.xml · derivative · entry 3 Redmond Cavan M. · CIK 0001420120 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,090 Underlying: Common Stock · 90,090 shares Expires 2015-02-25 F2 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F2 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 25, 2010 Filed Mar 2, 2010 02:01 UTC | PFIZER INC PFE · Entity 2863 | GrantCommon Stock | 22,284 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-10-006401 · doc4.xml · nonDerivative · entry 1 Redmond Cavan M. · CIK 0001420120 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,350 F1 · shares: The reported transaction constitutes the grant of restricted stock units, which are subject to certain vesting requirements. Read SEC document |
| October 30, 2009 Filed Nov 3, 2009 22:22 UTC | PFIZER INC PFE · Entity 2863 | GrantCommon Stock | 17,616 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-09-021562 · doc4.xml · nonDerivative · entry 2 Redmond Cavan M. · CIK 0001420120 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,148 F2 · shares: The reported transaction constitutes the grant of restricted stock units, which will vest and be settled in shares of Pfizer common stock on the third anniversary of the date of grant, provided that Mr. Redmond remains in the continuous employ of Pfizer until that anniversary date. This grant represents a portion of Mr. Redmond's Executive Long-Term Incentive Program Award for 2010. Read SEC document |
| October 30, 2009 Filed Nov 3, 2009 22:22 UTC | PFIZER INC PFE · Entity 2863 | GrantCommon Stock | 29,360 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-09-021562 · doc4.xml · nonDerivative · entry 1 Redmond Cavan M. · CIK 0001420120 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,532 F1 · shares: The reported transaction constitutes the grant of restricted stock units, which will vest and be settled in shares of Pfizer common stock on the third anniversary of the date of grant, provided that Mr. Redmond remains in the continuous employ of Pfizer until that anniversary date. This grant was made in connection with Mr. Redmond's election as Pfizer's Senior Vice President; Group President - Diversified Businesses effective October 16, 2009. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.